LATEST UPDATES » Intelligent Sensor Informs You to Change a Diaper via SMS       » University of Manchester & A*STAR ongoing partnership- Joint PhD programme       » Philippines Healthcare & New Digital Platform, MyDoc.       » Tapping on ASEAN'S Healthcare Opportunities through Singapore       » ASEAN: The New Playing Field for Global Medical Device Companies       » The Burden of Great Potential: the ASEAN Economic Community & Biopharmaceuticals       » When there is no Queen in the house, Asian Hive Bees Avoid Risky Foraging for Reproduction       » XELJANZTM (Tofacitinib Citrate), A new class of treatment for Rheumatoid Arthritis Approved in Singapore      
Cognoptix licenses AD detection technology
Cognoptix, which was known as Neuroptix until October, has exclusively licensed technology from the University of California, San Diego, which Cognoptix has developed into a non-invasive eye-scanning test for the early detection and diagnosis of Alzheimer's disease (AD). Cognoptix also revealed that it has established a Clinical Advisory Board, comprised of key opinion leaders from among the worldwide neuroscience community.

The Cognoptix Sapphire II system consists of a laser-based reading device and consumable ophthalmic ointment. The eye exam can be given by a general practitioner and only takes a few minutes to achieve a result. The Cognoptix drug/device combination is a novel, early-stage diagnostic for AD designed to allow treatment before significant neuronal loss and irreversible brain damage occurs. A ligand or contrast agent and software-controlled optical instrument allows for non-invasive detection and assessment of AD by measuring the hallmark of AD, amyloid beta, in the supranuclear region of the lens of the eye. The ligand is administered to the eye as an ophthalmic ointment and a proprietary Fluorescent Ligand Scanning instrument, provides an objective and quantitative measurement of amyloid beta in the patient's lens. Significantly faster and an order of magnitude less expensive than brain imaging, the test and diagnosis can be quickly completed in any physician's office, including general practitioners.

Cognoptix has a strong and com-prehensive patent portfolio covering diagnosis of amyloid beta-based diseases via ophthalmic imaging. The patent portfolio includes issued method and device patents, as well as pending composition of matter patents. In addition to UC San Diego, exclusive licenses have been acquired from Massachusetts General Hospital and Brigham & Women鈥檚 Hospital Boston.

There are more than 100 new AD drugs that are currently in various stages of research and development. The ability of the Cognoptix drug/device combination to identify and qualify patients for clinical study inclusion, as well as accurately and inexpensively track patient disease progression, may provide pharmaceutical companies with a significant competitive advantage in securing new AD drug approvals. It may also help identify and document differentiating pharmaceutical product performance attributes in Phase IV studies. The technology is currently in clinical trials.

Laura Attwood
Editor, Diagnostics Focus

Click here for the complete issue.


Credits to: American Chemical Society

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy